Abstract：Objectives To explore the characteristics and application values of serum anti-Müllerian hormone (AMH)and insulin resistance (IR) in patients with polycystic ovary syndrome (PCOS).Methods A retrospective analysis of 479 infertile patients who were treated in Dalian Maternal and Child Health Hospital from December 2018 to October 2019 was performed.In the research,patients diagnosed as PCOS were considered as PCOS group (315 cases),and other infertile patients were regarded as the control group (164 cases).Moreover,on the basis of the existence of IR,patients with PCOS were divided into PCOS-IR group (111 cases) and PCOS-NIR group (204 cases).The differences and significance of the ages,AMH,total testosterone (T),luteinizing hormone (LH),follicle stimulating hormone (FSH),estradiol(E2),triglyceride (TG),high density lipoprotein (HDL) and low density lipoprotein (LDL) were compared among three groups.Results The values of AMH,T,LH,E2,BMI,HOMA-IR,TG,LDL of PCOS group were higher than those of the control group,which were statistically significant (P＜0.05).FSH and HDL between the two groups were not statistically significant (P＞0.05).BMI,AMH,TG of PCOS-IR group were higher than those of PCOS-NIR group and the control group,which were statistically significant (P＜0.05).HDL of PCOS-IR group was lower than that of PCOS-NIR group and the control group,which was statistically significant (P＜0.05).LDL of PCOS-IR group was higher than that of the control group,which was statistically significant (P＜0.05).AMH,TG and LDL of PCOS-NIR group were higher than those of the control group,which were statistically significant (P＜0.05),and the differences of BMI and HDL between the two groups were not statistically significant (P＞0.05).Conclusions The level of AMH of patients with PCOS is significantly higher than that of patients of non-PCOS,which has a guiding significance for clinical diagnosis.insulin resistance can aggravate the abnormal lipid metabolism of PCOS,which should be paid great attention to and actively intervened in the therapy of patients with PCOS.
Dewailly D，Andersen CY，Balen A，et al.The physiology and clinical utility of anti-Müllerian hormone in women[J].Hum Reprod Update，2014，20（3）：370-385.
[3]
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome（PCOS）[J].Hum Reprod，2004，19（1）：41-47.
[4]
Genuth S，Alberti KG，Bennett P，et al.Follow-up report on the diagnosis of diabetes mellitus[J].Diabetes Care，2003，26（11）：3160-3167.
[6]
Marie LW，Anne LM，Kumar A，et al.Associations of different molecular forms of antimüllerian hormone and biomarkers of polycystic ovary syndrome and normal women[J].Fertil Steril，2019，112（1）：149-155.
[7]
Pigny P，Merlen E，Robert Y，et al.Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome：relationship to the ovarian follicle excess and to the follicular arrest[J].J Clin Endocrinol Metab，2003，88（12）：5957-5962.
[8]
Pellatt L，Hanna L，Brincat M，et al.Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries[J].J Clin Endocrinol Metab，2007，92（1）：240-245.
[9]
Jonard S，Dewailly D.The follicular excess in polycystic ovaries，due to intra-ovarian hyperandrogenism，may be the main culprit for the follicular arrest[J].Hum Reprod Update，2004，10（2）：107-117.
[10]
Groot PC，Dekkers OM，Romijn JA，et al.PCOS，coronary heart disease，stroke and the influence of obesity：a systematic review and meta-analysis[J].Hum Reprod Update，2011，17（4）：495-500.
[11]
Chen L，Xu WM，Zhang D.Association of abdominal obesity，insulin resistance，and oxidative stress in adipose tissue in women with polycystic ovary syndrome[J].Fertil Steril，2014，102（4）：1167-1174.
[12]
Yao L，Herlea-Pana O，Heuser-Baker J，et al.Roles of the chemokine system in development of obesity，insulin resistance，and cardiovascular disease[J].J Immunol Res，2014（2014）：181 450.
[13]
Kakoly NS，Khomami MB,Joham AE，et al.Ethnicity，obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS：a systematic review and meta-regression[J].Hum Reprod Update，2018，24（4）：455-467.
[14]
Behboudi-Gandevani S，Amiri M，Bidhendi YR，et al.The risk of metabolic syndrome in polycystic ovary syndrome：a systematic review and meta-analysis[J].Clin Endocrinol（Oxf），2017，88（2）：169-184.
[17]
Goodman NF，Cobin RH，Futterweit W，et al.American Association of Clinical Endocrinologists，American College of Endocrinology，and Androgen Excess and PCOS Society Disease State Clinical Review：Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome-Part 2[J].Endocr Pract，2015，21（12）：1415-1426.
京公网安备 11010502046607号